Accuray Incorporated, announced that for the first time in Europe the company showcased its latest offering, the CyberKnife VSI System, at ESTRO 29; the Annual Congress of the European Society for Therapeutic Radiology and Oncology in Barcelona, Spain. Also featured at this meeting were multiple presentations demonstrating this system’s best-in-class motion management capabilities for lung cancer care. In addition, two CyberKnife users were recognized for outstanding research.

Read the full story here

Spiracur, Inc. announced important results from a clinical study highlighting the efficacy of its SNaP Wound Care System for the treatment of chronic lower extremity wounds. The data was presented this week at the Fall 2010 Symposium on Advanced Wound Care (SAWC). The 12-center, 65-patient randomized controlled trial compared negative pressure wound therapy (NPWT) between the KCI Wound V.A.C. Therapy System and the SNaP Wound Care System for the treatment of chronic lower extremity wounds.

Read the full story here

Derma Sciences, Inc. has announced that patient screening in its DSC127 Phase 2 trial in diabetic foot ulcer healing will be completed tomorrow, and that enrollment in the trial will conclude on September 30. This randomized, double-blind, placebo controlled study of up to 75 patients will look at the percentage of diabetic ulcers completely healed over a 12-week period, among other outcomes.

Read the full story here

Millions of Americans seek relief from the signs of an aging complexion, which includes fine lines, wrinkles, enlarged pores, age spots, sun spots and uneven skin tone and texture. Laser Clinique has announced TotalFX fractional laser resurfacing technique. This procedure is the latest treatment for painlessly and efficiently eliminating the signs of aging. For today’s more active population, the prolonged healing time involved with conventional laser or face-lift surgery is not appropriate.

Read the full story here

A new study from the Queensland Institute of Medical Research (QIMR) has found that the major component of clove oil may be a promising lead as a new topical treatment for scabies. Plant essential oils have long been studied for their effects against mites, ticks, lice and mosquitoes. Researchers tested the clove oil and nutmeg oil on two different types of mites in the laboratory to see how many died from contact with the oils.

Read the full story here

BioAlliance Pharma SA announced the grant of a European patent protecting its product acyclovir Lauriad®. This patent is now validated in all European countries; this first patent validation is a major step and the procedures up to the grant are ongoing in the other major global areas, America and Asia. This patent specifically protects the muco-adhesive tablet containing acyclovir, its process for manufacturing and its clinical application.

Read the full story here

Medicis announced that FDA has approved additional strengths of SOLODYN(R) (minocycline HCl, USP) Extended Release Tablets in 55 mg, 80 mg and 105 mg dosages for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. The Company believes all forms of SOLODYN currently approved for use are covered by its patent rights.

Read the full story here

The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval in Hungary to commence a Phase IIa clinical trial with LytixarTM (LTX-109) treatment of skin infections caused by Gram positive bacteria. Preclinical models have demonstrated that LytixarTM is strongly bactericidal, being equally effective against wild-type as well as drug-resistant bacteria such as MRSA. Because of its unique membrane-lysing mechanism of action, there is no cross-resistance to other drugs.

Read the full story here